Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Surgical management of invasive gastric cancer

Paul F Mansfield, MD, FACS
Section Editors
Kenneth K Tanabe, MD
David I Soybel, MD
Deputy Editors
Diane MF Savarese, MD
Wenliang Chen, MD, PhD


Worldwide, the incidence of and mortality from gastric cancer has declined dramatically since the 1930s. (See "Epidemiology of gastric cancer", section on 'Incidence'.)

However, gastric cancer remains a lethal disease. In the United States, approximately 28,000 patients are diagnosed annually, and 10,960 are expected to die from the disease [1]. Global, country-specific rates of incidence and mortality are available from the World Health Organization (WHO) GLOBOCAN database.

Prognosis has improved only modestly over the last two decades, attributable to advances in surgical treatment, postoperative care, and multimodality therapy. In the US, the overall five-year survival rate for all stages combined was 27 percent between 2001 and 2007, compared with 15 percent between 1975 and 1977 [2]. The high mortality rate reflects the prevalence of advanced disease at presentation and relatively aggressive biology. Early lesions are usually asymptomatic and infrequently detected outside the realm of a screening program. (See "Clinical features, diagnosis, and staging of gastric cancer".)

An additional contributing factor to the persistently high mortality rate is the change in the distribution of cancers from the body and antrum to the proximal stomach during the past 20 years. Cancers involving the proximal stomach and esophagogastric junction (EGJ) have increased steadily at a rate exceeding that of any other cancer except melanoma and lung cancer. Aside from a correlation with increasing obesity, the reasons for this are unclear. Proximal lesions are biologically more aggressive and have a worse prognosis, stage for stage, than do distal gastric cancers [3]. This suggests that their pathogenesis differs from cancers arising in other parts of the stomach [4]. (See "Epidemiology of gastric cancer", section on 'Incidence' and "Epidemiology of gastric cancer", section on 'Change in histology pattern' and "Epidemiology, pathobiology, and clinical manifestations of esophageal cancer", section on 'Epidemiology' and "Epidemiology, pathobiology, and clinical manifestations of esophageal cancer", section on 'Pathobiology'.)

The classification and management of cancers arising at the EGJ have evolved over time. In the latest, eighth edition of the tumor, node, metastasis (TNM) staging manual [5], tumors arising at the EGJ with the tumor epicenter no more than 2 cm into the proximal stomach are staged as esophageal cancers (the so-called Siewert III EGJ tumors [6], see below). However, in contrast, EGJ tumors with their epicenter located more than 2 cm into the proximal stomach are staged as stomach cancers, as are all cardia cancers not involving the EGJ. Although implementation of the revised staging tables has been delayed until January 1, 2018 in the United States to allow for the updating of protocols, guidelines, and software, the scientific principles (including the reclassification of the boundary between esophagus and gastric tumors) is valid as of November 2016. Outside of the United States, the Union for International Cancer Control (UICC) has implemented the eighth edition changes as of January 1, 2017. (See "Diagnosis and staging of esophageal cancer", section on 'TNM staging criteria' and "Clinical features, diagnosis, and staging of gastric cancer", section on 'TNM staging criteria'.)

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Aug 22, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin 2017; 67:7.
  2. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10.
  3. Wanebo HJ, Kennedy BJ, Chmiel J, et al. Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993; 218:583.
  4. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med 1995; 333:32.
  5. Ajani JA, In H, Sano T, et al.. Stomach.. In: AJCC Cancer Staging Manual, 8th, Amin MB. (Ed), AJCC, Chicago 2017. p.203.
  6. Rüdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg 2000; 232:353.
  7. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345:725.
  8. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355:11.
  9. Yoshida S, Saito D. Gastric premalignancy and cancer screening in high-risk patients. Am J Gastroenterol 1996; 91:839.
  10. Sue-Ling HM, Johnston D, Martin IG, et al. Gastric cancer: a curable disease in Britain. BMJ 1993; 307:591.
  11. Sussman SK, Halvorsen RA Jr, Illescas FF, et al. Gastric adenocarcinoma: CT versus surgical staging. Radiology 1988; 167:335.
  12. Power DG, Schattner MA, Gerdes H, et al. Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer. J Am Coll Surg 2009; 208:173.
  13. National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on February 27, 2016).
  14. Oh CA, Bae JM, Oh SJ, et al. Long-term results and prognostic factors of gastric cancer patients with only positive peritoneal lavage cytology. J Surg Oncol 2012; 105:393.
  15. De Andrade JP, Mezhir JJ. The critical role of peritoneal cytology in the staging of gastric cancer: an evidence-based review. J Surg Oncol 2014; 110:291.
  16. Bonenkamp JJ, Songun I, Hermans J, van de Velde CJ. Prognostic value of positive cytology findings from abdominal washings in patients with gastric cancer. Br J Surg 1996; 83:672.
  17. Bando E, Yonemura Y, Takeshita Y, et al. Intraoperative lavage for cytological examination in 1,297 patients with gastric carcinoma. Am J Surg 1999; 178:256.
  18. Bentrem D, Wilton A, Mazumdar M, et al. The value of peritoneal cytology as a preoperative predictor in patients with gastric carcinoma undergoing a curative resection. Ann Surg Oncol 2005; 12:347.
  19. Ribeiro U Jr, Safatle-Ribeiro AV, Zilberstein B, et al. Does the intraoperative peritoneal lavage cytology add prognostic information in patients with potentially curative gastric resection? J Gastrointest Surg 2006; 10:170.
  20. Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol 2011; 18:1575.
  21. Gill RS, Al-Adra DP, Nagendran J, et al. Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity. J Surg Oncol 2011; 104:692.
  22. Canbay E, Mizumoto A, Ichinose M, et al. Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. Ann Surg Oncol 2014; 21:1147.
  23. American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.117.
  24. Wanebo HJ, Kennedy BJ, Winchester DP, et al. Gastric carcinoma: does lymph node dissection alter survival? J Am Coll Surg 1996; 183:616.
  25. Coburn NG, Swallow CJ, Kiss A, Law C. Significant regional variation in adequacy of lymph node assessment and survival in gastric cancer. Cancer 2006; 107:2143.
  26. Datta J, Lewis RS Jr, Mamtani R, et al. Implications of inadequate lymph node staging in resectable gastric cancer: a contemporary analysis using the National Cancer Data Base. Cancer 2014; 120:2855.
  27. Bouvier AM, Haas O, Piard F, et al. How many nodes must be examined to accurately stage gastric carcinomas? Results from a population based study. Cancer 2002; 94:2862.
  28. Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1,038 patients. Ann Surg 2000; 232:362.
  29. Woo Y, Goldner B, Ituarte P, et al. Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. J Am Coll Surg 2017; 224:546.
  30. Windham TC, Termuhlen PM, Ajani JA, Mansfield PF. Adenocarcinoma of the stomach in patients age 35 years and younger: no impact of early diagnosis on survival outcome. J Surg Oncol 2002; 81:118.
  31. Higgins GA, Serlin O, Amadeo JH, et al. Gastric cancer: factors in survival. Surg Gastrointest 1976; 10:393.
  32. Henning GT, Schild SE, Stafford SL, et al. Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma. Int J Radiat Oncol Biol Phys 2000; 46:589.
  33. Hamy A, Letessier E, Bizouarn P, et al. Study of survival and prognostic factors in patients undergoing resection for gastric linitis plastica: a review of 86 cases. Int Surg 1999; 84:337.
  34. Haugstvedt TK, Viste A, Eide GE, Söreide O. Norwegian multicentre study of survival and prognostic factors in patients undergoing curative resection for gastric carcinoma. The Norwegian Stomach Cancer Trial. Br J Surg 1993; 80:475.
  35. Najam AA, Yao JC, Lenzi R, et al. Linitis plastica is common in women and in poorly differentiated and signet ring cell histologies: an analysis of 217 patients (abstract). Proc Am Soc Clin Oncol 2002; 21:166a.
  36. Furukawa H, Hiratsuka M, Iwanaga T, et al. Extended surgery--left upper abdominal exenteration plus Appleby's method--for type 4 gastric carcinoma. Ann Surg Oncol 1997; 4:209.
  37. Blackham AU, Swords DS, Levine EA, et al. Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Ann Surg Oncol 2016; 23:1203.
  38. Anderson ID, MacIntyre IM. Symptomatic outcome following resection of gastric cancer. Surg Oncol 1995; 4:35.
  39. Wu CW, Chiou JM, Ko FS, et al. Quality of life after curative gastrectomy for gastric cancer in a randomised controlled trial. Br J Cancer 2008; 98:54.
  40. Iivonen MK, Mattila JJ, Nordback IH, Matikainen MJ. Long-term follow-up of patients with jejunal pouch reconstruction after total gastrectomy. A randomized prospective study. Scand J Gastroenterol 2000; 35:679.
  41. Tyrväinen T, Sand J, Sintonen H, Nordback I. Quality of life in the long-term survivors after total gastrectomy for gastric carcinoma. J Surg Oncol 2008; 97:121.
  42. Bozzetti F, Marubini E, Bonfanti G, et al. Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study Group. Ann Surg 1999; 230:170.
  43. Gouzi JL, Huguier M, Fagniez PL, et al. Total versus subtotal gastrectomy for adenocarcinoma of the gastric antrum. A French prospective controlled study. Ann Surg 1989; 209:162.
  44. Buhl K, Schlag P, Herfarth C. Quality of life and functional results following different types of resection for gastric carcinoma. Eur J Surg Oncol 1990; 16:404.
  45. Pu YW, Gong W, Wu YY, et al. Proximal gastrectomy versus total gastrectomy for proximal gastric carcinoma. A meta-analysis on postoperative complications, 5-year survival, and recurrence rate. Saudi Med J 2013; 34:1223.
  46. Noguchi Y, Yoshikawa T, Tsuburaya A, et al. Is gastric carcinoma different between Japan and the United States? Cancer 2000; 89:2237.
  47. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011; 14:101.
  48. Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359:453.
  49. Wagner PK, Ramaswamy A, Rüschoff J, et al. Lymph node counts in the upper abdomen: anatomical basis for lymphadenectomy in gastric cancer. Br J Surg 1991; 78:825.
  50. Roukos DH, Kappas AM. Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 2002; 81:59.
  51. Bunt AM, Hermans J, Smit VT, et al. Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 1995; 13:19.
  52. de Manzoni G, Verlato G, Roviello F, et al. The new TNM classification of lymph node metastasis minimises stage migration problems in gastric cancer patients. Br J Cancer 2002; 87:171.
  53. Smith DD, Schwarz RR, Schwarz RE. Impact of total lymph node count on staging and survival after gastrectomy for gastric cancer: data from a large US-population database. J Clin Oncol 2005; 23:7114.
  54. Jiang L, Yang KH, Guan QL, et al. Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: a meta-analysis. J Surg Oncol 2013; 107:807.
  55. Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg 1988; 75:110.
  56. Cuschieri A, Fayers P, Fielding J, et al. Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group. Lancet 1996; 347:995.
  57. Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med 1999; 340:908.
  58. Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer. Br J Surg 2014; 101:23.
  59. El-Sedfy A, Dixon M, Seevaratnam R, et al. Personalized Surgery for Gastric Adenocarcinoma: A Meta-analysis of D1 versus D2 Lymphadenectomy. Ann Surg Oncol 2015; 22:1820.
  60. Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 2010; 11:439.
  61. Robertson CS, Chung SC, Woods SD, et al. A prospective randomized trial comparing R1 subtotal gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994; 220:176.
  62. Sano T, Sasako M, Yamamoto S, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501. J Clin Oncol 2004; 22:2767.
  63. Kulig J, Popiela T, Kolodziejczyk P, et al. Standard D2 versus extended D2 (D2+) lymphadenectomy for gastric cancer: an interim safety analysis of a multicenter, randomized, clinical trial. Am J Surg 2007; 193:10.
  64. Yonemura Y, Wu CC, Fukushima N, et al. Randomized clinical trial of D2 and extended paraaortic lymphadenectomy in patients with gastric cancer. Int J Clin Oncol 2008; 13:132.
  65. Maeta M, Yamashiro H, Saito H, et al. A prospective pilot study of extended (D3) and superextended para-aortic lymphadenectomy (D4) in patients with T3 or T4 gastric cancer managed by total gastrectomy. Surgery 1999; 125:325.
  66. Mocellin S, McCulloch P, Kazi H, et al. Extent of lymph node dissection for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2015; :CD001964.
  67. Hartgrink HH, van de Velde CJ, Putter H, et al. Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 2004; 22:2069.
  68. Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999; 79:1522.
  69. Petrelli NJ. The debate is over; it's time to move on. J Clin Oncol 2004; 22:2041.
  70. Wu CW, Hsiung CA, Lo SS, et al. Nodal dissection for patients with gastric cancer: a randomised controlled trial. Lancet Oncol 2006; 7:309.
  71. Smith JW, Shiu MH, Kelsey L, Brennan MF. Morbidity of radical lymphadenectomy in the curative resection of gastric carcinoma. Arch Surg 1991; 126:1469.
  72. Hundahl SA, Macdonald JS, Benedetti J, et al. Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002; 9:278.
  73. Coburn NG, Swallow C, Quan ML, et al. Significant regional variation in treatment and survival of gastric cancer (abstract). J Clin Oncol 2005; 23:309s.
  74. Baxter NN, Tuttle TM. Inadequacy of lymph node staging in gastric cancer patients: a population-based study. Ann Surg Oncol 2005; 12:981.
  75. Bilimoria KY, Talamonti MS, Wayne JD, et al. Effect of hospital type and volume on lymph node evaluation for gastric and pancreatic cancer. Arch Surg 2008; 143:671.
  76. Kampschöer GH, Maruyama K, van de Velde CJ, et al. Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients. Br J Surg 1989; 76:905.
  77. Bollschweiler E, Boettcher K, Hoelscher AH, et al. Preoperative assessment of lymph node metastases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 1992; 79:156.
  78. Mahar AL, McLeod RS, Kiss A, et al. A systematic review of the effect of institution and surgeon factors on surgical outcomes for gastric cancer. J Am Coll Surg 2012; 214:860.
  79. Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.
  80. Smith DL, Elting LS, Learn PA, et al. Factors influencing the volume-outcome relationship in gastrectomies: a population-based study. Ann Surg Oncol 2007; 14:1846.
  81. Enzinger PC, Benedetti JK, Meyerhardt JA, et al. Impact of hospital volume on recurrence and survival after surgery for gastric cancer. Ann Surg 2007; 245:426.
  82. Csendes A, Burdiles P, Rojas J, et al. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery 2002; 131:401.
  83. Brady MS, Rogatko A, Dent LL, Shiu MH. Effect of splenectomy on morbidity and survival following curative gastrectomy for carcinoma. Arch Surg 1991; 126:359.
  84. Wanebo HJ, Kennedy BJ, Winchester DP, et al. Role of splenectomy in gastric cancer surgery: adverse effect of elective splenectomy on longterm survival. J Am Coll Surg 1997; 185:177.
  85. Chen XZ, Wen L, Rui YY, et al. Long-term survival outcomes of laparoscopic versus open gastrectomy for gastric cancer: a systematic review and meta-analysis. Medicine (Baltimore) 2015; 94:e454.
  86. Viñuela EF, Gonen M, Brennan MF, et al. Laparoscopic versus open distal gastrectomy for gastric cancer: a meta-analysis of randomized controlled trials and high-quality nonrandomized studies. Ann Surg 2012; 255:446.
  87. Ding J, Liao GQ, Liu HL, et al. Meta-analysis of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer. J Surg Oncol 2012; 105:297.
  88. Lin JX, Huang CM, Zheng CH, et al. Surgical outcomes of 2041 consecutive laparoscopic gastrectomy procedures for gastric cancer: a large-scale case control study. PLoS One 2015; 10:e0114948.
  89. Qiu J, Pankaj P, Jiang H, et al. Laparoscopy versus open distal gastrectomy for advanced gastric cancer: a systematic review and meta-analysis. Surg Laparosc Endosc Percutan Tech 2013; 23:1.
  90. Chen K, Xu XW, Zhang RC, et al. Systematic review and meta-analysis of laparoscopy-assisted and open total gastrectomy for gastric cancer. World J Gastroenterol 2013; 19:5365.
  91. Wei HB, Wei B, Qi CL, et al. Laparoscopic versus open gastrectomy with D2 lymph node dissection for gastric cancer: a meta-analysis. Surg Laparosc Endosc Percutan Tech 2011; 21:383.
  92. Zeng YK, Yang ZL, Peng JS, et al. Laparoscopy-assisted versus open distal gastrectomy for early gastric cancer: evidence from randomized and nonrandomized clinical trials. Ann Surg 2012; 256:39.
  93. Kim W, Kim HH, Han SU, et al. Decreased Morbidity of Laparoscopic Distal Gastrectomy Compared With Open Distal Gastrectomy for Stage I Gastric Cancer: Short-term Outcomes From a Multicenter Randomized Controlled Trial (KLASS-01). Ann Surg 2016; 263:28.
  94. Hu Y, Huang C, Sun Y, et al. Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial. J Clin Oncol 2016; 34:1350.
  95. Honda M, Hiki N, Kinoshita T, et al. Long-term Outcomes of Laparoscopic Versus Open Surgery for Clinical Stage I Gastric Cancer: The LOC-1 Study. Ann Surg 2016; 264:214.
  96. Kitagawa Y, Fujii H, Mukai M, et al. Intraoperative lymphatic mapping and sentinel lymph node sampling in esophageal and gastric cancer. Surg Oncol Clin N Am 2002; 11:293.
  97. Ohdaira H, Nimura H, Mitsumori N, et al. Validity of modified gastrectomy combined with sentinel node navigation surgery for early gastric cancer. Gastric Cancer 2007; 10:117.
  98. Takeuchi H, Kitagawa Y. Sentinel lymph node biopsy in gastric cancer. Cancer J 2015; 21:21.
  99. Kitagawa Y, Takeuchi H, Takagi Y, et al. Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. J Clin Oncol 2013; 31:3704.
  100. Miyashiro I, Hiratsuka M, Sasako M, et al. High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302. Gastric Cancer 2014; 17:316.
  101. Wang Z, Dong ZY, Chen JQ, Liu JL. Diagnostic value of sentinel lymph node biopsy in gastric cancer: a meta-analysis. Ann Surg Oncol 2012; 19:1541.
  102. Ryu KW, Eom BW, Nam BH, et al. Is the sentinel node biopsy clinically applicable for limited lymphadenectomy and modified gastric resection in gastric cancer? A meta-analysis of feasibility studies. J Surg Oncol 2011; 104:578.
  103. Takeuchi H, Kitagawa Y. Is lymphadenectomy a predictor or savior for patients with gastric cancer? Ann Surg Oncol 2010; 17:1257.
  104. https://clinicaltrials.gov/ct2/show/NCT01804998?term=NCT01804998&rank=1 (Accessed on September 16, 2015).
  105. https://clinicaltrials.gov/ct2/show/NCT01544413?term=NCT01544413&rank=1 (Accessed on September 16, 2015).
  106. Fujitani K, Ajani JA, Crane CH, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol 2007; 14:2010.
  107. An JY, Kim KM, Kim YM, et al. Surgical complications in gastric cancer patients preoperatively treated with chemotherapy: their risk factors and clinical relevance. Ann Surg Oncol 2012; 19:2452.
  108. Badgwell B, Cormier JN, Krishnan S, et al. Does neoadjuvant treatment for gastric cancer patients with positive peritoneal cytology at staging laparoscopy improve survival? Ann Surg Oncol 2008; 15:2684.
  109. Okabe H, Ueda S, Obama K, et al. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 2009; 16:3227.
  110. Lorenzen S, Panzram B, Rosenberg R, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol 2010; 17:2733.
  111. Mezhir JJ, Shah MA, Jacks LM, et al. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol 2010; 17:3173.
  112. Verdecchia A, Mariotto A, Gatta G, et al. Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003; 39:1603.
  113. Maruyama K, Okabayashi K, Kinoshita T. Progress in gastric cancer surgery in Japan and its limits of radicality. World J Surg 1987; 11:418.
  114. Strong VE, Song KY, Park CH, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg 2010; 251:640.
  115. Gill S, Shah A, Le N, et al. Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol 2003; 21:2070.
  116. Davis PA, Sano T. The difference in gastric cancer between Japan, USA and Europe: what are the facts? what are the suggestions? Crit Rev Oncol Hematol 2001; 40:77.
  117. Petrelli F, Ghidini M, Barni S, et al. Prognostic Role of Primary Tumor Location in Non-Metastatic Gastric Cancer: A Systematic Review and Meta-Analysis of 50 Studies. Ann Surg Oncol 2017; 24:2655.
  118. Sano T, Coit DG, Kim HH, et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017; 20:217.
  119. Bria E, De Manzoni G, Beghelli S, et al. A clinical-biological risk stratification model for resected gastric cancer: prognostic impact of Her2, Fhit, and APC expression status. Ann Oncol 2013; 24:693.
  120. Cascinu S, Labianca R, Barone C, et al. Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst 2007; 99:601.
  121. Bose, D, Baddgwell, B, Cormier, JN, et al. Association of neoadjuvant chemoradiation with improved survival in resectable gastric cancer (abstract). Data presented at the 2009 ASCO Gastrointestinal Cancers Symposium, San francisco, CA, January 15-17, 2009. Abstract available online at http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=63&abstractID=10135 (Accessed on December 02, 2010).
  122. Lee WJ, Lee WC, Houng SJ, et al. Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan. World J Surg 1995; 19:707.
  123. Macdonald JS. Gastric cancer: Nagoya is not New York. J Clin Oncol 2011; 29:4348.
  124. Markar SR, Karthikesalingam A, Jackson D, Hanna GB. Long-term survival after gastrectomy for cancer in randomized, controlled oncological trials: comparison between West and East. Ann Surg Oncol 2013; 20:2328.
  125. Hundahl SA, Stemmermann GN, Oishi A. Racial factors cannot explain superior Japanese outcomes in stomach cancer. Arch Surg 1996; 131:170.
  126. Wang J, Sun Y, Bertagnolli MM. Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database. Ann Surg Oncol 2015; 22:2965.
  127. Kattan MW, Karpeh MS, Mazumdar M, Brennan MF. Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003; 21:3647.
  128. Peeters KC, Kattan MW, Hartgrink HH, et al. Validation of a nomogram for predicting disease-specific survival after an R0 resection for gastric carcinoma. Cancer 2005; 103:702.
  129. Novotny AR, Schuhmacher C, Busch R, et al. Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 2006; 243:74.
  130. Han DS, Suh YS, Kong SH, et al. Nomogram predicting long-term survival after d2 gastrectomy for gastric cancer. J Clin Oncol 2012; 30:3834.
  131. Hirabayashi S, Kosugi S, Isobe Y, et al. Development and external validation of a nomogram for overall survival after curative resection in serosa-negative, locally advanced gastric cancer. Ann Oncol 2014; 25:1179.
  132. Kim Y, Spolverato G, Ejaz A, et al. A nomogram to predict overall survival and disease-free survival after curative resection of gastric adenocarcinoma. Ann Surg Oncol 2015; 22:1828.
  133. Bencivenga M, Verlato G, Han DS, et al. Validation of two prognostic models for recurrence and survival after radical gastrectomy for gastric cancer. Br J Surg 2017; 104:1235.
  134. Dikken JL, Coit DG, Baser RE, et al. Performance of a nomogram predicting disease-specific survival after an R0 resection for gastric cancer in patients receiving postoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 2014; 88:624.
  135. Dikken JL, Baser RE, Gonen M, et al. Conditional probability of survival nomogram for 1-, 2-, and 3-year survivors after an R0 resection for gastric cancer. Ann Surg Oncol 2013; 20:1623.
  136. Wang SY, Yeh CN, Lee HL, et al. Clinical impact of positive surgical margin status on gastric cancer patients undergoing gastrectomy. Ann Surg Oncol 2009; 16:2738.
  137. Nagata T, Ichikawa D, Komatsu S, et al. Prognostic impact of microscopic positive margin in gastric cancer patients. J Surg Oncol 2011; 104:592.
  138. Bickenbach KA, Gonen M, Strong V, et al. Association of positive transection margins with gastric cancer survival and local recurrence. Ann Surg Oncol 2013; 20:2663.
  139. Li F, Zhang R, Liang H, et al. The pattern and risk factors of recurrence of proximal gastric cancer after curative resection. J Surg Oncol 2013; 107:130.
  140. Ikoma N, Chen HC, Wang X, et al. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol 2017; 24:2679.
  141. Smyth EC, Verheij M, Allum W, et al. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2016; 27:v38.
  142. Eom BW, Ryu KW, Lee JH, et al. Oncologic effectiveness of regular follow-up to detect recurrence after curative resection of gastric cancer. Ann Surg Oncol 2011; 18:358.
  143. Yoon SS. How closely should we follow gastric cancer patients following surgical resection? Ann Surg Oncol 2011; 18:311.
  144. Badgwell B, Cormier JN, Xing Y, et al. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol 2009; 16:42.
  145. Kodera Y, Ito S, Yamamura Y, et al. Follow-up surveillance for recurrence after curative gastric cancer surgery lacks survival benefit. Ann Surg Oncol 2003; 10:898.
  146. Miller RC, Haddock MG, Gunderson LL, et al. Intraoperative radiotherapy for treatment of locally advanced and recurrent esophageal and gastric adenocarcinomas. Dis Esophagus 2006; 19:487.
  147. An JY, Youn HG, Ha TK, et al. Clinical significance of tumor location in remnant gastric cancers developed after partial gastrectomy for primary gastric cancer. J Gastrointest Surg 2008; 12:689.
  148. Ohashi M, Katai H, Fukagawa T, et al. Cancer of the gastric stump following distal gastrectomy for cancer. Br J Surg 2007; 94:92.
  149. Yoo CH, Noh SH, Shin DW, et al. Recurrence following curative resection for gastric carcinoma. Br J Surg 2000; 87:236.
  150. Shchepotin I, Evans SR, Shabahang M, et al. Radical treatment of locally recurrent gastric cancer. Am Surg 1995; 61:371.
  151. Morgagni P, Gardini A, Marrelli D, et al. Gastric stump carcinoma after distal subtotal gastrectomy for early gastric cancer: experience of 541 patients with long-term follow-up. Am J Surg 2015; 209:1063.
  152. Sinning C, Schaefer N, Standop J, et al. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment. Eur J Surg Oncol 2007; 33:133.
  153. Tran TB, Hatzaras I, Worhunsky DJ, et al. Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer? J Surg Oncol 2015; 112:877.
  154. Irino T, Hiki N, Ohashi M, et al. Characteristics of gastric stump cancer: A single hospital retrospective analysis of 262 patients. Surgery 2016; 159:1539.
  155. Linhares E, Monteiro M, Kesley R, et al. Major hepatectomy for isolated metastases from gastric adenocarcinoma. HPB (Oxford) 2003; 5:235.
  156. Cheon SH, Rha SY, Jeung HC, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol 2008; 19:1146.
  157. Koga R, Yamamoto J, Ohyama S, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol 2007; 37:836.
  158. Okano K, Maeba T, Ishimura K, et al. Hepatic resection for metastatic tumors from gastric cancer. Ann Surg 2002; 235:86.
  159. Shirabe K, Wakiyama S, Gion T, et al. Hepatic resection for the treatment of liver metastases in gastric carcinoma: review of the literature. HPB (Oxford) 2006; 8:89.
  160. Ambiru S, Miyazaki M, Ito H, et al. Benefits and limits of hepatic resection for gastric metastases. Am J Surg 2001; 181:279.